1. Search Result
Search Result
Results for "

Ac1 ras Inhibitors

" in MedChemExpress (MCE) Product Catalog:

259

Inhibitors & Agonists

2

Screening Libraries

1

Biochemical Assay Reagents

12

Peptides

2

Inhibitory Antibodies

16

Natural
Products

61

Recombinant Proteins

3

Isotope-Labeled Compounds

20

Antibodies

2

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145830

    Adenylate Cyclase Neurological Disease
    AC1-IN-1 is a potent and selective Adenylyl cyclase type 1 (AC1) inhibitor with an IC50 of 0.54 µM. AC1-IN-1 displays modest antiallodynic effects in a mouse model of inflammatory pain. AC1-IN-1 has CNS activity [1].
    <em>AC1</em>-IN-<em>1</em>
  • HY-14425

    HTS 09836

    Adenylate Cyclase Neurological Disease
    NB001 (HTS 09836) is an adenylcyclase 1 (AC1) inhibitor which has effect on neural and non-neural pain by modulating AC1 activity [1].
    NB001
  • HY-N10772

    Calcium Channel Calmodulin Adenylate Cyclase Neurological Disease Inflammation/Immunology
    Albanin A, a flavonoid, suppresses glutamate release by decreasing Ca 2+/calmodulin/adenylate Cyclase 1 (AC1) activation in synaptosomes and exerts neuroprotective effect in vivo. Albanin A has anti-inflflammatory activity [1].
    Albanin A
  • HY-101279
    ST034307
    2 Publications Verification

    Adenylate Cyclase Neurological Disease
    ST034307 is a potent and selective adenylyl cyclase 1 (AC1) inhibitor, with IC50 of 2.3 μM.
    ST034307
  • HY-128433

    Casein Kinase Neurological Disease
    CK1-IN-3 (compound 51) is a AC1 inhibitor with an IC50s 2.22 µM for CK-1δ [1] .
    CK<em>1</em>-IN-3
  • HY-138294
    RAS/RAS-RAF-IN-1
    1 Publications Verification

    Ras Raf Cancer
    RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity [1].
    <em>RAS</em>/<em>RAS</em>-RAF-IN-<em>1</em>
  • HY-103430

    Dopamine Receptor 5-HT Receptor Adenylate Cyclase Neurological Disease
    SKF-83566 hydrobromide is a potent, blood-brain permeable and orally active D1-like dopamine receptor (D1DR) antagonist and a weaker competitive antagonist at the vascular 5-HT2 receptor (Ki=11 nM) [1] . SKF-83566 is a competitive DAT (dopamine transporter) inhibitor with an IC50 of 5.7 μM . SKF-83566 also shows selective inhibition for adenylyl cyclase 2 (AC2) over AC1 and AC5 in the isolated rabbit thoracic aorta . SKF-83566 can be used for the research of parkinson’s disease and nicotine craving alleviation .
    SKF-83566 hydrobromide
  • HY-103430A
    SKF-83566
    1 Publications Verification

    Dopamine Receptor 5-HT Receptor Adenylate Cyclase Neurological Disease
    SKF-83566 is a potent, blood-brain permeable and orally active D1-like dopamine receptor (D1DR) antagonist and a weaker competitive antagonist at the vascular 5-HT2 receptor (Ki=11 nM) [1] . SKF-83566 is a competitive DAT (dopamine transporter) inhibitor with an IC50 of 5.7 μM . SKF-83566 also shows selective inhibition for adenylyl cyclase 2 (AC2) over AC1 and AC5 in the isolated rabbit thoracic aorta . SKF-83566 can be used for research of parkinson’s disease and nicotine craving alleviation .
    SKF-83566
  • HY-18674

    Ras Cancer
    K-Ras-IN-1 is a K-Ras inhibitor. K-Ras-IN-1 binds K-Ras (WT), K-Ras (G12D), K-Ras (G12V), and H-Ras. K-Ras-IN-1 has the potential to be used in research on pancreatic, colon and lung cancer [1].
    K-<em>Ras</em>-IN-<em>1</em>
  • HY-148878

    Ras Cancer
    Ras modulator-1 is a modulator of Ras. Ras modulator-1 is an active compound extracted from patent US20120302581 [1].
    <em>Ras</em> modulator-<em>1</em>
  • HY-101295
    Pan-RAS-IN-1
    5 Publications Verification

    Ras Cancer
    Pan-RAS-IN-1 is a pan-Ras inhibitor that disrupts the interaction of Ras proteins and their effectors.
    Pan-<em>RAS</em>-IN-<em>1</em>
  • HY-P2157

    Ras Cancer
    Ras Inhibitory Peptide (VPPPVPPRRR) is a Ras inhibitor with antitumor activity [1].
    <em>Ras</em> Inhibitory Peptide
  • HY-122862
    RAS inhibitor Abd-7
    1 Publications Verification

    Ras Cancer
    RAS inhibitor Abd-7, a potent RAS-binding compound (Kd=51 nM), is a RAS-effector protein-protein interaction (PPI) inhibitor. RAS inhibitor Abd-7 interacts with RAS inside the cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signaling. RAS inhibitor Abd-7 impairs the PPI of various mutant KRAS proteins with PI3K, CRAF and RALGDS as well as NRAS Q61H and HRAS G12V [1].
    <em>RAS</em> inhibitor Abd-7
  • HY-156363

    Ras Cancer
    K-Ras-IN-2 (Compound CHI-000-667) is a K-Ras antagonist, and can be used for tumor research [1].
    K-<em>Ras</em>-IN-2
  • HY-115555

    Phosphodiesterase (PDE) Cancer
    K-Ras-PDEδ-IN-1 is a novel and potent competitive K-Ras-PDEδ inhibitor. K-Ras-PDEδ-IN-1 binds to the farnesyl binding pocket of PDEδ with a low nanomolar Kd of 8 nM [1].
    K-<em>Ras</em>-PDEδ-IN-<em>1</em>
  • HY-129523
    PROTAC K-Ras Degrader-1
    1 Publications Verification

    PROTACs Ras Cancer
    PROTAC K-Ras Degrader-1 (Compound 518) is a PROTAC. PROTAC K-Ras Degrader-1 can effectively degrades K-Ras based on Cereblon E3 ligand, exhibits ≥70% degradation efficacy in SW1573 cells [1].
    PROTAC K-<em>Ras</em> Degrader-<em>1</em>
  • HY-18605

    Ras Cancer
    K-Ras G12C-IN-2 is an irreversible covalent K-Ras G12C inhibitor.
    K-<em>Ras</em> G12C-IN-2
  • HY-129775

    Target Protein Ligand-Linker Conjugates Cancer
    K-Ras ligand-Linker Conjugate 1 incorporates a ligand for K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 1 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells [1].
    K-<em>Ras</em> ligand-Linker Conjugate <em>1</em>
  • HY-129776

    Target Protein Ligand-Linker Conjugates Cancer
    K-Ras ligand-Linker Conjugate 2 incorporates a ligand for K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 2 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells [1].
    K-<em>Ras</em> ligand-Linker Conjugate 2
  • HY-18606

    Ras Cancer
    K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.
    K-<em>Ras</em> G12C-IN-3
  • HY-130707

    Target Protein Ligand-Linker Conjugates Cancer
    K-Ras ligand-Linker Conjugate 3 (Compound 001371) incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 3 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells [1].
    K-<em>Ras</em> ligand-Linker Conjugate 3
  • HY-130822

    Target Protein Ligand-Linker Conjugates Cancer
    K-Ras ligand-Linker Conjugate 4 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 4 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells [1].
    K-<em>Ras</em> ligand-Linker Conjugate 4
  • HY-130823

    Target Protein Ligand-Linker Conjugates Cancer
    K-Ras ligand-Linker Conjugate 5 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 5 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells [1].
    K-<em>Ras</em> ligand-Linker Conjugate 5
  • HY-130991

    Target Protein Ligand-Linker Conjugates Cancer
    K-Ras ligand-Linker Conjugate 6 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 6 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells [1].
    K-<em>Ras</em> ligand-Linker Conjugate 6
  • HY-129189

    Ras Cancer
    RAS GTPase inhibitor 1 (example 51) is a RAS GTPase inhibitor with anti-tumor activity, extracted from patent WO2018212774A1. RAS GTPase inhibitor 1 (example 51) exhibits an EC50 less than 1 μM for at least one nucleotide exchange and an IC50 less than 1 μM in H727 cells [1].
    <em>RAS</em> GTPase inhibitor <em>1</em>
  • HY-12446

    Ras Cancer
    K-Ras (G12C) inhibitor 9 is an allosteric inhibitor of the K-Ras (G12C) [1].
    K-<em>Ras</em>(G12C) inhibitor 9
  • HY-18604

    Ras Cancer
    K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1.
    K-<em>Ras</em> G12C-IN-<em>1</em>
  • HY-18707

    Ras Apoptosis Cancer
    K-Ras(G12C) inhibitor 12 is a K-Ras(G12C) inhibitor. K-Ras(G12C) inhibitor 12 acts on H1792 cells with an EC50 of 0.32 μM.
    K-<em>Ras</em>(G12C) inhibitor 12
  • HY-107841

    Ras Cancer
    K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the K-Ras(G12C) [1].
    K-<em>Ras</em>(G12C) inhibitor 6
  • HY-128044

    B581

    Farnesyl Transferase Cancer
    Ftase inhibitor I (B581) is a potent, selective and peptidomimetic farnesyl transferase (FTase) inhibitor. Ftase inhibitor I shows selectivity for FTase over geranylgeranyl isoprenoid (Ras-GG) or the fatty acid myristate (Myr-Ras) [1].
    Ftase inhibitor I
  • HY-148439

    ras-IN-2

    Ras Cancer
    RMC-6236 (Compound A122) is a potent RAS(ON) MULTI inhibitor and can be used for the research of cancer [1].
    RMC-6236
  • HY-RS05088

    Small Interfering RNA (siRNA) Others

    FRA10AC1 Human Pre-designed siRNA Set A contains three designed siRNAs for FRA10AC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FRA10AC1 Human Pre-designed siRNA Set A
    FRA10AC1 Human Pre-designed siRNA Set A
  • HY-161024

    AQB

    Histone Methyltransferase Cancer
    AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of Tazemetostat in endometrial cancer [1].
    <em>AC1</em>Q3QWB
  • HY-155954

    Apoptosis Autophagy Cancer
    UCM-1336 is a potent ICMT inhibitor, with an IC50 of 2 μM. UCM-1336 induces mislocalization of endogenous Ras, decreases Ras activation and induces cell death by autophagy and apoptosis [1].
    UCM-1336
  • HY-124306
    ML-099
    2 Publications Verification

    CID-888706

    Ras Cancer
    ML-099 (CID-888706) is a pan Ras-related GTPases activator that can activate Rac1, cell division cycle 42, Ras, Rab7, and Rab-2A [1].
    ML-099
  • HY-128771

    Ras Cancer
    K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRAS G12C [1].
    K-<em>Ras</em> G12C-IN-4
  • HY-123673
    MCP110
    1 Publications Verification

    Ras Raf Cancer
    MCP110 is an inhibitor of Ras/Raf-1 interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors [1].
    MCP110
  • HY-14718

    ras2410; 4SC-201

    HDAC Cancer
    Resminostat (RAS2410; 4SC-201) is a potent inhibitor of HDAC1, HDAC3 and HDAC6, with mean IC50 values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC50 of 877 nM.
    Resminostat
  • HY-150658S

    Isotope-Labeled Compounds Others
    DMT-2′O-TBDMS-rA(ac)-1- 15N phosphoramidite is the 15N labeled DMT-2′O-TBDMS-rA(ac) phosphoramidite[1].
    DMT-2′O-TBDMS-rA(<em>ac)-1</em>-15N phosphoramidite
  • HY-147229

    Ras Cancer
    GDC-6036-NH is from patent WO2020097537A2, and a precursor of compound 17 a/b. Compound 17 a/b is a RAS inhibitor and can be used in cancer research [1].
    GDC-6036-NH
  • HY-W048303

    Antibiotic Infection Cancer
    L-Azatyrosine is an antitumor antibiotic isolated from Streptomyces chibaensis. L-Azatyrosine can restore normal phenotypic behavior to transformed cells bearing oncogenic Ras genes [1] .
    L-Azatyrosine
  • HY-129273

    Farnesyl Transferase Cancer
    L-731735 is a selective FPTase inhibitor that can inhibit ras-dependent cell transformation. L-731735 can be used in cancer research [1].
    L-731735
  • HY-151566

    Ras Farnesyl Transferase Fungal Infection
    Antifungal agent 46 (compound 2f) is a potent antifungal agent. Antifungal agent 46 prevents Ras signaling by inhibiting protein farnesyltransferase [1].
    Antifungal agent 46
  • HY-119264A

    HIF/HIF Prolyl-Hydroxylase Ras Cancer
    PRLX-93936 dihydrochloride (Compound 16) is a HIF-1α inhibitor with anticancer activity. PRLX-93936 can inhibit the activated Ras pathway and can be used in the study of relapsed or refractory multiple myeloma [1] .
    PRLX-93936 dihydrochloride
  • HY-136579

    ERK-IN-3

    ERK Cancer
    ASN007 (ERK-IN-3) is a potent and orally active inhibitor of ERK. ASN007 inhibits ERK1/2 with low single-digit nM IC50 values. ASN007 can be used for the research of cancers driven by RAS mutations [1].
    ASN007
  • HY-136579A

    ERK-IN-3 benzenesulfonate

    ERK Cancer
    ASN007 (ERK-IN-3) benzenesulfonate is a potent and orally active inhibitor of ERK. ASN007 benzenesulfonate inhibits ERK1/2 with low single-digit nM IC50 values. ASN007 benzenesulfonate can be used for the research of cancers driven by RAS mutations [1].
    ASN007 benzenesulfonate
  • HY-157740

    HDAC Cancer
    XSJ-10 is a HDAC inhibitor containing a RAS/RAF protein interfering unit, with IC50s of 0.05 and 0.04 μM in PANC-1 cells and HT-29 cells. XSJ-10 can effectively induce the apoptosis of cancer cells and suppress the tumor by strongly inhibiting the RAS-RAF-MEK-ERK signaling pathway and the acetylation level of HDAC3 [1].
    XSJ-10
  • HY-16059

    (+)-Arglabin

    NOD-like Receptor (NLR) Farnesyl Transferase Autophagy Inflammation/Immunology Cancer
    Arglabin ((+)-Arglabin), a natural product isolated from Artemisia glabella, is a NLRP3 inflammasome inhibitor. Arglabin shows anti-inflammatory and antitumor activities [1]. The antitumor activity of Arglabin proceeds through its inhibition of farnesyl transferase which leads to the activation of RAS proto-oncogene .
    Arglabin
  • HY-156498

    Ras Cancer
    RMC-7977 is a reversible, tri-complex RAS inhibitor with broad spectrum activity for both mutant and wild-type (WT) KRAS, NRAS, and HRAS variants.RMC-7977 can lead to tumor regressions and was well tolerated in diverse RAS-addicted preclinical cancer models. RMC-7977 also can inhibit the growth of KRAS G12C cancer models [1].
    RMC-7977
  • HY-156500

    ICMT Cancer
    ICMT-IN-1 (compound 75) is an inhibitor of ICMT (IC50=0.0013 μM). ICMT-IN-1 dose-dependently induces ICMT accumulation in the cytoplasm of HCT-116 cells and inhibits the proliferation of multiple cancer cell lines expressing K-Ras and N-Ras [1].
    ICMT-IN-<em>1</em>

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: